ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
Yodod
|
1.2K |
623K |
13 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
1.2K
|
623K
|
13
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Phase 2 trial shows significant improvements in Pitt Hopkins
|
|
Yodod
|
160 |
83K |
13 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
160
|
83K
|
13
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Comment on research report
|
|
Yodod
|
316 |
166K |
49 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
316
|
166K
|
49
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
Yodod
|
1.2K |
623K |
56 |
14/01/24 |
14/01/24 |
ASX - By Stock
|
1.2K
|
623K
|
56
|
|
ASX - By Stock
|
NEU |
Re:
Ann: P2 trial shows significant improvements in Phelan-McDermid
|
|
Yodod
|
210 |
89K |
52 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
210
|
89K
|
52
|
|
ASX - By Stock
|
NEU |
Re:
Ann: P2 trial shows significant improvements in Phelan-McDermid
|
|
Yodod
|
210 |
89K |
24 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
210
|
89K
|
24
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
Yodod
|
315 |
159K |
6 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
315
|
159K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Yodod
|
10K |
4.9M |
25 |
26/10/23 |
26/10/23 |
ASX - By Stock
|
10K
|
4.9M
|
25
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Yodod
|
10K |
4.9M |
18 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
10K
|
4.9M
|
18
|
|
ASX - By Stock
|
NEU |
Re:
Daybue Rollout
|
|
Yodod
|
128 |
64K |
12 |
05/05/23 |
05/05/23 |
ASX - By Stock
|
128
|
64K
|
12
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Yodod
|
10K |
4.9M |
23 |
18/03/23 |
18/03/23 |
ASX - By Stock
|
10K
|
4.9M
|
23
|
|
ASX - By Stock
|
NEU |
Re:
Shorting the sucker-rally
|
|
Yodod
|
342 |
120K |
16 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
342
|
120K
|
16
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Yodod
|
10K |
4.9M |
37 |
15/02/23 |
15/02/23 |
ASX - By Stock
|
10K
|
4.9M
|
37
|
|